We are a clinical-stage biopharmaceutical company focused on changing the lives of patients living with nonalcoholic steatohepatitis (NASH) and other liver and metabolic disorders. Our teams in the US and Israel are developing highly differentiated medicines that address unmet medical needs based on robust research. Our lead product candidate, BIO89-100, is a novel long-acting glycopegylated fibroblast growth factor 21 (FGF21) analogue.

Current Opportunities

San Francisco, CA
Closes: 24 Nov 2021 08:31
San Francisco, CA
Closes: 07 Nov 2021 12:41
San Francisco, CA
Closes: 05 Nov 2021 14:11
San Francisco, CA
Closes: 04 Sep 2021 14:53
Head of Regulatory Affairs
89Bio- Head/Senior Director of Regulatory Affairs
San Francisco, CA
Closes: 31 Jul 2021 10:27
This site is powered by SnapHire (www.snaphire.com)